GB0121151D0 - Anti-cancer compounds - Google Patents

Anti-cancer compounds

Info

Publication number
GB0121151D0
GB0121151D0 GB0121151A GB0121151A GB0121151D0 GB 0121151 D0 GB0121151 D0 GB 0121151D0 GB 0121151 A GB0121151 A GB 0121151A GB 0121151 A GB0121151 A GB 0121151A GB 0121151 D0 GB0121151 D0 GB 0121151D0
Authority
GB
United Kingdom
Prior art keywords
cancer compounds
cancer
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0121151A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Priority to GB0121151A priority Critical patent/GB0121151D0/en
Publication of GB0121151D0 publication Critical patent/GB0121151D0/en
Priority to EP10185923A priority patent/EP2311850A1/en
Priority to AT02755281T priority patent/ATE483722T1/en
Priority to EP02755281A priority patent/EP1421105B1/en
Priority to JP2003525018A priority patent/JP4328202B2/en
Priority to PT02755267T priority patent/PT1420809E/en
Priority to PCT/GB2002/003961 priority patent/WO2003020300A1/en
Priority to ES02755267T priority patent/ES2373644T3/en
Priority to US10/487,874 priority patent/US7528141B2/en
Priority to PCT/GB2002/003979 priority patent/WO2003020748A1/en
Priority to KR1020107007266A priority patent/KR20100043294A/en
Priority to KR1020047002994A priority patent/KR100983962B1/en
Priority to AT02755267T priority patent/ATE526028T1/en
Priority to EP02755267A priority patent/EP1420809B1/en
Priority to EP10177988A priority patent/EP2332962A1/en
Priority to BRPI0212215A priority patent/BRPI0212215B8/en
Priority to US10/487,871 priority patent/US7297701B2/en
Priority to DK02755281.9T priority patent/DK1421105T3/en
Priority to MXPA04001905A priority patent/MXPA04001905A/en
Priority to AU2002321576A priority patent/AU2002321576B2/en
Priority to DK02755267.8T priority patent/DK1420809T3/en
Priority to PT02755281T priority patent/PT1421105E/en
Priority to DE60237902T priority patent/DE60237902D1/en
Priority to CA2458813A priority patent/CA2458813C/en
Priority to ZA2004/01587A priority patent/ZA200401587B/en
Priority to US11/710,985 priority patent/US7863284B2/en
Priority to US11/727,242 priority patent/US7705006B2/en
Priority to US12/588,910 priority patent/US8486955B2/en
Priority to US12/659,286 priority patent/US8063056B2/en
Priority to US12/801,853 priority patent/US8552016B2/en
Priority to CY20111100015T priority patent/CY1111078T1/en
Priority to CY20111101237T priority patent/CY1112143T1/en
Ceased legal-status Critical Current

Links

GB0121151A 2001-08-31 2001-08-31 Anti-cancer compounds Ceased GB0121151D0 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
GB0121151A GB0121151D0 (en) 2001-08-31 2001-08-31 Anti-cancer compounds
US10/487,871 US7297701B2 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta [G]quinazoline compounds
EP10177988A EP2332962A1 (en) 2001-08-31 2002-08-30 Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions
CA2458813A CA2458813C (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazoline compounds
EP02755281A EP1421105B1 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta¬g quinazoline compounds
JP2003525018A JP4328202B2 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta [G] quinazoline compound
PT02755267T PT1420809E (en) 2001-08-31 2002-08-30 Use of cyclopenta[g]quinazoline derivatives for treating cancer
PCT/GB2002/003961 WO2003020300A1 (en) 2001-08-31 2002-08-30 Use of cyclopenta[g]quinazoline derivatives for treating cancer
DK02755281.9T DK1421105T3 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta [g] quinazoline compounds
US10/487,874 US7528141B2 (en) 2001-08-31 2002-08-30 Use of cyclopenta[g]quinazoline derivatives for treating cancer
PCT/GB2002/003979 WO2003020748A1 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazoline compounds
KR1020107007266A KR20100043294A (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazoline compounds
KR1020047002994A KR100983962B1 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazoline compounds
AT02755281T ATE483722T1 (en) 2001-08-31 2002-08-30 ANTI-CANCER CYCLOPENTAAG CHINAZOLINE DERIVATIVES
EP02755267A EP1420809B1 (en) 2001-08-31 2002-08-30 Use of cyclopenta[g]quinazoline derivatives for treating cancer
EP10185923A EP2311850A1 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazoline compounds
BRPI0212215A BRPI0212215B8 (en) 2001-08-31 2002-08-30 cyclopenta[g]quinazoline anticancer compounds, use thereof for the treatment of cancer and pharmaceutical composition comprising said compound
AT02755267T ATE526028T1 (en) 2001-08-31 2002-08-30 USE OF CYCLOPENTAÄGÜCHINAZOLINE DERIVATIVES FOR CANCER TREATMENT
ES02755267T ES2373644T3 (en) 2001-08-31 2002-08-30 USE OF CYCLOPENTA DERIVATIVES [G] QUINAZOLINE FOR THE TREATMENT OF C�? NCER.
MXPA04001905A MXPA04001905A (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazoline compounds.
AU2002321576A AU2002321576B2 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[G]quinazoline compounds
DK02755267.8T DK1420809T3 (en) 2001-08-31 2002-08-30 Use of cyclopenta [G] quinazoline derivatives for the treatment of cancer
PT02755281T PT1421105E (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta¬g quinazoline compounds
DE60237902T DE60237902D1 (en) 2001-08-31 2002-08-30 ANTIQUE CYCLOPENTAiG CHINAZOLINE DERIVATIVES
ZA2004/01587A ZA200401587B (en) 2001-08-31 2004-02-26 Anti-cancer cyclopenta[g]quinazoline compounds
US11/710,985 US7863284B2 (en) 2001-08-31 2007-02-27 Anti-cancer cyclopenta[G]quinazoline compounds
US11/727,242 US7705006B2 (en) 2001-08-31 2007-03-26 Anti-cancer cyclopenta[g]quinazoline compounds
US12/588,910 US8486955B2 (en) 2001-08-31 2009-11-02 Anti-cancer cyclopenta [g] quinazoline compounds
US12/659,286 US8063056B2 (en) 2001-08-31 2010-03-03 Anti-cancer cyclopenta [g]quinazonline compounds
US12/801,853 US8552016B2 (en) 2001-08-31 2010-06-29 Anti-cancer cyclopenta(g)quinazoline compounds
CY20111100015T CY1111078T1 (en) 2001-08-31 2011-01-04 ANTI-CANCER COMPOUNDS [G] KINAZOLIN
CY20111101237T CY1112143T1 (en) 2001-08-31 2011-12-13 USE OF KYKLOPENTA [G] KINAZOLIN PRODUCTS FOR CANCER TREATMENT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0121151A GB0121151D0 (en) 2001-08-31 2001-08-31 Anti-cancer compounds

Publications (1)

Publication Number Publication Date
GB0121151D0 true GB0121151D0 (en) 2001-10-24

Family

ID=9921321

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0121151A Ceased GB0121151D0 (en) 2001-08-31 2001-08-31 Anti-cancer compounds

Country Status (1)

Country Link
GB (1) GB0121151D0 (en)

Similar Documents

Publication Publication Date Title
GB0107758D0 (en) Anti-cancer compounds
AU2002349297A8 (en) Statin-like compounds
GB0101996D0 (en) Organtic compounds
GB0112324D0 (en) Compounds
GB0102668D0 (en) Compounds
GB0108102D0 (en) Compounds
GB0119474D0 (en) Compounds
GB0102673D0 (en) Compounds
GB0102665D0 (en) Compounds
GB0119472D0 (en) Compounds
EP1458669A4 (en) Neuorologically-active compounds
GB0115178D0 (en) Compounds
GB0118364D0 (en) Compounds
GB0119473D0 (en) Compounds
GB0108097D0 (en) Compounds
GB0129387D0 (en) Anti-cancer compounds
GB0121151D0 (en) Anti-cancer compounds
GB0105098D0 (en) Compounds
GB0015117D0 (en) Anti-cancer compounds
GB0007636D0 (en) Anti-cancer compounds
GB0105737D0 (en) Compounds
GB0115438D0 (en) Compounds
GB0104401D0 (en) Compounds
GB0104398D0 (en) Compounds
GB0104397D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)